Optimizing drug therapy comprises genotyping subject for cytochrome P metabolizer status, administering pharmaceutical composition, collecting blood samples, measuring pharmacodynamic responses, comparing pharmacokinetic and pharmacodynamic parameters followed by employing statistical analysis
	DIWAKAR D; GUPTA P K; KUMAR A; MISHRA A K; SINGH A
	2025-03-28
专利权人	DIWAKAR D (DIWA-Individual) ; GUPTA P K (GUPT-Individual) ; KUMAR A (KUMA-Individual) ; MISHRA A K (MISH-Individual) ; SINGH A (SING-Individual)
申请日期	2025-03-28
专利号	IN202511029881-A
成果简介	NOVELTY - Optimizing drug therapy comprises: (a) genotyping a subject for cytochrome P450 2D6 (CYP2D6) metabolizer status using pharmacogenomic kit to classify the subject as poor, intermediate, extensive, or ultra-rapid metabolizer; (b) administering pharmaceutical composition to the subject; (c) collecting blood samples from the subject; (d) analyzing collected samples to quantify pharmacokinetic parameters; (e) measuring pharmacodynamic responses by assessing physiological parameters relevant to the therapeutic action of drug; (f) comparing pharmacokinetic and pharmacodynamic parameters between standard fixed-dose regimen and individualized dose regimen; (g) adjusting drug dosage based on pharmacokinetic and pharmacodynamic responses of the subject; and (h) employing statistical analysis, including independent t-tests, one-way Analysis of Variance (ANOVA) to validate the significance of observed differences between personalized and standard dosing regimens. USE - Method for optimizing drug therapy through personalized dosing. ADVANTAGE - The method achieves optimal therapeutic response with reduced toxicity, improved clinical outcomes, improved drug absorption, distribution, and elimination, and improved adherence, and reduces risks associated with improper dosing, and reduces the risk of overdose or insufficient drug action. DETAILED DESCRIPTION - Method for optimizing drug therapy through personalized dosing comprises: (a) genotyping a subject for CYP2D6 metabolizer status using a commercial pharmacogenomic kit to classify the subject as a poor, intermediate, extensive, or ultra-rapid metabolizer; (b) administering a pharmaceutical composition to the subject, where the dose is individualized based on the subject's metabolizer classification; (c) collecting blood samples from the subject at predetermined time intervals post-dose to determine plasma drug concentrations; (d) analyzing the collected plasma samples using liquid chromatography-mass spectrometry (LC-MS) to quantify pharmacokinetic parameters such as maximum plasma concentration (Cmax), time to reach Cmax (Tmax), and area under the plasma concentration-time curve (AUC); (e) measuring pharmacodynamic responses by assessing physiological parameters relevant to the therapeutic action of the drug at baseline and predefined post-dose intervals; (f) comparing pharmacokinetic and pharmacodynamic parameters between a standard fixed-dose regimen and the individualized dose regimen; (g) adjusting the drug dosage based on pharmacokinetic and pharmacodynamic responses of the subject to achieve an optimized therapeutic outcome while minimizing adverse effects; and (h) employing statistical analysis, including independent t-tests, one-way Analysis of Variance (ANOVA), and post hoc corrections, to validate the significance of observed differences between personalized and standard dosing regimens.
IPC 分类号	A61B-005/00 ; G16C-020/30 ; G16H-050/20 ; G16H-050/50 ; G16H-070/40
国家	印度
专业领域	信息技术
语种	英语
成果类型	专利
文献类型	科技成果
条目标识符	http://119.78.100.226:8889/handle/3KE4DYBR/13451
专题	中国科学院新疆生态与地理研究所
作者单位	1.DIWAKAR D (DIWA-Individual) 2.GUPTA P K (GUPT-Individual) 3.KUMAR A (KUMA-Individual) 4.MISHRA A K (MISH-Individual) 5.SINGH A (SING-Individual)
推荐引用方式 GB/T 7714	DIWAKAR D,GUPTA P K,KUMAR A,et al. Optimizing drug therapy comprises genotyping subject for cytochrome P metabolizer status, administering pharmaceutical composition, collecting blood samples, measuring pharmacodynamic responses, comparing pharmacokinetic and pharmacodynamic parameters followed by employing statistical analysis. IN202511029881-A[P]. 2025.

条目包含的文件
条目无相关文件。

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。